Immix Biopharma, Inc.: Mizuho cuts target price to $23 from $26
IMMX•Mizuho cut its target price for Immix Biopharma to $23 from $26.
Related News
CCC Intelligent Solutions Q3 revenue rises 10%, beats estimates
CCC•
Instacart Q3 revenue tops estimates; to be acquired by DoorDash
CART•
LKQ publishes third-quarter 2026 earnings presentation
LKQ•
Howmet lifts annual forecasts on robust demand for aircraft parts
HWM•
Acadian Asset Management announces availability of third-quarter 2026 earnings release
AAMI•